

WHY MAINTAIN LIGHT CHAIN ISOTYPES? THE INFLUENCE OF HEAVY  
CHAIN ISOTYPE AND COMPLEMENTARY DETERMINING REGION LENGTHS

UPON LIGHT CHAIN ISOTYPE IN *XENOPUS LAEVIS*

A Thesis

by

NATALIE JO JACOBS

Submitted to the Office of Graduate and Professional Studies of  
Texas A&M University  
in partial fulfillment of the requirements for the degree of

MASTER OF SCIENCE

Chair of Committee,	Michael F. Criscitiello
Co-Chair of Committee,	C. Jane Welsh
Committee Member,	Scott V. Dindot
Head of Department,	Roger Smith III

December 2015

Major Subject: Biomedical Sciences

Copyright 2015 Natalie Jo Jacobs

## ABSTRACT

Different immunoglobulin (Ig) heavy chain (H) isotypes have distinct functions, but so far it is unclear if Ig light (L) chains follow the same pattern. It is usually assumed that form follows function; but if this is true, then why have different IgL isotypes with no known functional differences? In this study we investigate IgH and IgL isotype preferential binding and complementary determining region (CDR) lengths to try to address this question using the African clawed frog, *Xenopus laevis*, as a model. Amphibians exhibit IgH isotype class switch at a single IgH locus and have an additional, more divergent, IgL isotype ( $\sigma$ ) plus the two found in mammals ( $\lambda$  and  $\kappa$ ). We used quantitative PCR (qPCR) analysis of IgH isotype of B cells sorted by surface IgL isotype expression to find evidence of preferential use of IgL isotype by IgH isotype. We found a relative skewing in the Ig $\kappa$  cells for IgY, in the Ig $\lambda$  cells for IgX, the Ig $\sigma$  cells for IgM, and corroborated published immunoprecipitations showing that IgY and Ig $\sigma$  do not pair with gene expression data of the IgL isotype sorted cells. Our data also suggests that the exaggerated CDR1 of IgHV families III and VII and the long CDR2 of Ig $\sigma$  may cramp IgH CDR3, making the IgHV III/VII-Ig $\sigma$  pairing less common. While these data do not resolve the conundrum of multiple IgL isotype maintenance in vertebrates, they do show that in a tetrapod with several IgH and several IgL isotype options, IgL isotype use is not random.

## DEDICATION

This is dedicated to the ones I love. To my father, who I miss dearly; my mother, who has stood by me through it all; and to my love, whose unending patience and kindness exceeds that of a Saint. I love you all.

And in memory of Dr. Ashley Peterson who lit a path to guide my way. Your light and smile shall live on in our hearts forever.

## ACKNOWLEDGEMENTS

I would like to thank my committee chair, Dr. Michael Criscitiello, co-chair Dr. Jane Welsh, and committee member Dr. Scott Dindot for their guidance and support throughout the course of this research.

Thanks also go to my friends and colleagues in the lab and the department faculty and staff for making my time at Texas A&M University a great experience

This work was supported by awards from the NIH (AI56963) to MFC and (R01OD0549) to MFF and YO, and the NSF (IOS1257829). Thad Deiss was supported in part by a graduate merit fellowship. The work of Dr. Christina Du and Dr. Sara Mashoof was funded by individual student research grants through the Texas A&M College of Veterinary Medicine and Biomedical Sciences.

## TABLE OF CONTENTS

	Page
ABSTRACT .....	ii
DEDICATION .....	iii
ACKNOWLEDGEMENTS .....	iv
TABLE OF CONTENTS .....	v
LIST OF FIGURES.....	vii
LIST OF TABLES .....	viii
1. INTRODUCTION AND LITERATURE REVIEW.....	1
2. MATERIALS AND METHODS .....	3
2.1 Animals and cell harvest .....	3
2.2 Cell sorting .....	4
2.3 Quantitative PCR.....	5
2.4 Sampling of IgH CDR3 from IgL isotype sorts by plasmid cloning ...	6
2.5 Immunogenetic analysis.....	6
2.6 Molecular modeling .....	7
2.7 Flow cytometry .....	7
3. RESULTS.....	9
3.1 IgH/IgL isotype pairing.....	9
3.2 IgH CDR3 length with different IgL isotypes.....	9
3.3 <i>X. laevis</i> IgH isotype V, D, and J use.....	11
3.4 IgL isotype exclusion .....	12
4. DISCUSSION .....	14
4.1 IgL isotype use is far from random in <i>X. laevis</i> .....	14
4.2 Hints of IgL isotype distinct physiology .....	16
4.3 Evolution of IgL isotype physiology.....	18

	Page
5. CONCLUSIONS .....	21
REFERENCES .....	23
APPENDIX A .....	27
APPENDIX B .....	53

## LIST OF FIGURES

	Page
Figure 1	IgH isotype message is not equal in cells sorted for IgL isotype ..... 27
Figure 2	CDR3H lengths not significantly different amongst isotypes ..... 28
Figure 3	IgH V families III and VII used preferentially with Ig $\kappa$ , not Ig $\sigma$ ..... 29
Figure 4	SCFV homology modeling supports CDRH1-CDRL2 steric hindrance constraining CDR3H..... 30
Figure 5	Flow cytometry ..... 31
Figure 6	Model of development of isotype skewing..... 40
Figure 7	Unique CDR3 amino acid sequences cloned from IgL isotype sorts .... 41
Figure 8	Nucleotide alignments of IgH isotype clone CDR3s..... 49
Figure 9	Correlation of N/P nucleotide additions with CDR3 length ..... 51
Figure 10	Use of D and J segments in IgH isotype of particular IgH and IgL isotype sort ..... 52

## LIST OF TABLES

	Page
Table 1 IgH clones sequenced by IgL isotype sort.....	53
Table 2 Use of long CDR1 VH families III and VI by IgL isotype.....	53
Table 3 Primers used.....	54
Table 4 Limits of IgH genomic V and J sequences.....	55
Table 5 Cells and RNA recovered after IgL isotype sorts .....	56



## 1. INTRODUCTION AND LITERATURE REVIEW

Antibodies, or Immunoglobulins, are the crucial antigen receptor of the vertebrate humoral adaptive immune system. They protect the host from pathogens in many ways including neutralization, opsonization, and activation of the complement cascade. The structure of an antibody consists of two heavy and two light peptide chains covalently connected by disulfide bonds. The N-terminal domains of both Ig light (IgL) and Ig heavy (IgH) are greatly variable for antigen binding and the constant (C) terminal domains are nearly constant within isotypes. There are three CDRs that are part of the V domain. CDR3 is the most diverse and includes the H VDJ gene segments. Many IgH isotypes have been described in vertebrates but all seem to be orthologous with either IgM, IgD, IgT (the dedicated mucosal isotype of teleost (bony) fish (1)), IgX/A (the dedicated mucosal type of tetrapods (2)), or the IgY/IgG/IgE family (reviewed in (3)). Four IgL isotypes have been described. Ig $\lambda$  and Ig $\kappa$  are used by most vertebrate groups, whereas  $\sigma$  and  $\sigma$ -cart are only found in fishes and amphibians (4).

The constant regions of IgH isotypes impart functional distinction to antibodies, but why have multiple IgL isotypes? The extra loci certainly complicate haplotype exclusion, although it has been suggested that the additional loci provide a larger canvas upon which receptor editing can paint, possibly making the confounding path to clonal receptor expression on a lymphocyte worthwhile for central B cell tolerance (5). Additional means of diversification of the antibody repertoire seems a logical explanation for IgL isotypes. But that would favor simpler diversification of divergent V

families at one locus as is seen with IgH isotype, and this mechanism is not supported by comparative data for IgL isotypes (6). If distinct IgL isotype loci are being maintained evolutionarily, discrete physiology should be expected of their products. There is little evidence for distinct roles for mammalian Ig $\kappa$  and Ig $\lambda$ , but hints can be found in the literature (e.g., (7)). In *X. laevis*, IgL isotype (Ig $\sigma$ ) only associated with two of the three IgH isotypes (IgM and IgX), displaying a propensity in this amphibian of IgL $\sigma$  for the two T-independent IgH isotypes expressed in the intestine (8-10). Work in skate showed a large disparity in the ratio of IgL isotype expression in the intestine (11). We have suggested that the principal selection component could be the heterodimerization requirements of the two V domains (12). These ideas were first tested in an animal with clear IgH/IgL isotype preference demonstrated at the protein level (8), *X. laevis*.

## 2. METHODS

### 2.1 Animals and cell harvest

The African clawed frog, *X. laevis*, served as the model for this study. The original frogs were acquired from *Xenopus* Express (Brooksville, FL). Outbred *X. laevis* were spawned and maintained as previously described (13). Briefly successive generations were bred using human chorionic gonadotropin hormone (Sigma-Aldrich, St Louis, MO). Two XenoPlus (Techniplast, Buguggiate, Italy) recirculating aquatic husbandry systems were used to support the frogs. A sinking pellet diet was used for adult frogs and a powdered diet for tadpoles (*Xenopus* Express). The room was kept on a 12 hour light cycle at a temperature of 23°C.

Four unimmunized adult frogs age 10-12 months were selected for each of three cell sort experiments and euthanized with MS-222 (tricaine methyl sulfonate, Argent, Redmond WA) overdose. Spleens were dissected and dissociated with tweezers on a steel mesh in a small petri dish filled with 2mL Magnetic Activated Cell Sorting (MACS), Miltenyi Biotech, San Diego CA) buffer (0.5% bovine serum albumin, 2mM EDTA, in phosphate buffered saline adjusted for amphibian salinity (65:35 mammalian PBS to water)). Splenocytes were counted manually with a hemocytometer or with a Cellometer Auto 1000 (Nexcelom Bioscience, Lawrence MA). All frog procedures and care were approved by the Texas A&M Institutional Animal Care and Use Committee (Animal Protocol 2011-303).

## 2.2 Cell sorting

Anti-frog IgL monoclonal antibodies (mAb) used for sorting were developed in the laboratory of Louis Du Pasquier: mouse anti-frog Ig $\kappa$  409B8, mouse anti-frog Ig $\lambda$  1E9, and mouse anti-frog Ig $\sigma$  13B2 (8). Splenocytes were diluted in primary antibody (600 $\mu$ L in 1:10 amphibian PBS) and incubated for one hour on ice inverting every 15 minutes. They were then washed with 10mL of MACS buffer and centrifuged for 10 minutes at 10°C at 1000rpm twice. The cells were resuspended in MACS buffer (80 $\mu$ L per 10<sup>7</sup> starting cells). Goat anti-mouse IgG MicroBeads (Miltenyi Biotec) were added (20 $\mu$ L per 10<sup>7</sup> starting cells), mixed well, and incubated for one hour on ice inverting every 15 minutes. They were then washed with 2mL MACS buffer per 10<sup>7</sup> starting cells and centrifuged twice as before. Cell pellets were resuspended in 500 $\mu$ L MACS buffer per 10<sup>7</sup> starting cells. Cells were passed through a MACS Pre-Separation Filter (Miltenyi Biotec) pre-wet with 1mL MACS buffer to remove clumps. A MACS LS separation column (Miltenyi Biotec) was placed in a magnetic stand and wet with 3mL MACS buffer. Cells were loaded 3mL at a time and gravity-fed into 15mL collection tubes on ice. Cells on magnetized column were washed with 3mL MACS buffer three times. Flow through was collected as negative populations. Columns were then removed from the magnetic stand, 5mL MACS buffer was applied to column, and cells were immediately pushed with plunger into a new collection tube for positive sort. A second round of MACS with a new column was used to double purify the IgL isotype positive populations. Cells were again counted to determine the final number of negative and positive cells. Cell loss was high in the two rounds of selection, usually around 80%.

### 2.3 Quantitative PCR

Using the RNeasy kit (Qiagen, Germantown MD) per the manufacturer's instructions, RNA was purified from the sorted cells. The first strand complementary (c) DNA was synthesized using random hexamer priming with SuperscriptIII (Life Technologies, Grand Island NY), and both RNA and cDNA were measured for quality and quantity using the NanoDrop 2000c spectrophotometer (Life Technologies). Standard PCR was performed to evaluate the representative quality of the cDNA using the primers in Table 3. The PCR conditions were 30 cycles, 30s, 95°C denaturation, 30s annealing and 1m extension at 68°C, with initial 3m denaturation and final 5m extension, where annealing was adjusted for each amplicon to 5°C below the lower of the Tms listed in Table 3.

The qPCR reactions were performed with 50ng of cDNA with the recommended 5x HOT FIREPol Eva Green HRM Mix (without ROX, Solis Biodyne, Tartu Estonia) per manufacturer's instructions. The qPCR samples were cycled 45 times with the annealing temperature set to 55°C on a LightCycler 480 (Roche, Basel Switzerland), followed by melting curve analysis. The Roche LightCycler software was utilized for raw data acquisition and calculation of Ct (threshold cycle) values. Changes in gene expression were estimated using the  $2^{-\Delta\Delta Ct}$  method (14), with  $\beta_2$ -microglobulin as the reference gene. IgL isotype expression in positive and negative sorts was subjected to median normalization to create normalization ratios for IgH isotype expression accounting for sort efficiency (15).

## **2.4 Sampling of IgH CDR3 from IgL isotype sorts by plasmid cloning**

Standard Taq DNA polymerase (New England BioLabs, Ipswich MA) was used in 25uL reactions with primers in Table 3 then transferred to a C1000 Thermal Cycler (Bio-Rad). The products were run on a 0.8% agarose gel and the desired DNA products were identified with ultraviolet light and cut from the gel for cloning. Topoisomerase cloning and transformation were executed following the TOPO TA Cloning user manual (Life Technologies). White or light blue colonies were selected for overnight cultures for plasmid minipreps. Plasmid DNA was purified using the ZR Plasmid Miniprep™-Classic kit (Zymo Research, Irvine CA) followed by *EcoRI* (Promega, Madison WI) digestion. The digested samples were evaluated on the NanoDrop 2000c spectrophotometer and analyzed on an agarose gel. BigDye V3.1 (Life Technologies) sequence reactions were made with M13 forward primers and cycled per the manufacturer's recommendations. The BigDye XTerminator Purification Kit™ (Life Technologies) was used to prepare the products for sequencing by the DNA Technologies Core Lab in the Department of Veterinary Pathobiology at Texas A&M University.

## **2.5 Immunogenetic analysis**

Sequence data was managed in the Geneious bioinformatic suite version 7.1 (Biomatters, Auckland New Zealand). Lengths of CDR3 were calculated as the exclusive number of amino acids between the conserved cysteine of the YxC motif of the variable (V) and the first glycine of the GxG motif of the joining (J) (16). IgH variable (V), diversity (D) and joining (J) gene sequences were called as previously

assigned (17-19) for *X. laevis* and limits of genomic coding sequence was confirmed in the JGI genomic assembly version 7.1 by finding the conserved heptamer (CACAGTG) and nonamer (ACAAAAACC) motifs of the recombination signal sequences (Table 4). Four bases of identity were required to count in a D segment versus N/P addition, which most likely skews the N/P count higher. Sequences were submitted to the National Center for Biotechnological Information.

## **2.6 Molecular modeling**

Hypothetical single-chain fragment variable molecules (scFv) were created in silico to model the tertiary and quaternary interactions between various frog IgH and IgL isotype, V family, and CDR3 length combinations. These were made by bridging frog IGLV and IgHV in two possible orientations: with a linker at the carboxyl terminus of the IgHV to the amino terminus of the IGLV and vice versa, with the IGL-linker-IgH oriented constructs yielding better results as judged by QMEAN scores (20). Linkers of varying length and amino acid content were also tried before settling on “GGGSGGGSGGGS” (21), again for better QMEAN scores. Structural templates were chosen by SWISS-MODEL (22, 23) and the resulting amino acid alignments visually inspected but no manual adjustments were necessary. All models used had global mean quality estimation (GMQE) scores of 0.75 or above. Coordinates of homology models were visualized in Geneious and images generated in that software suite.

## **2.7 Flow cytometry**

Adult *X. laevis* splenocytes ( $5 \times 10^5$  cells/per treatment) were stained with 1:100 dilutions of one of the mAbs described above: mouse anti-frog Ig $\kappa$  409B8, mouse anti-

frog Ig $\lambda$  1E9, and mouse anti-frog Ig $\sigma$  13B2 (8). Cells were then washed 3x with staining buffer before staining with 1:100 FITC labeled rabbit anti-mouse IgG<sub>1</sub> (Sigma, Saint Louis MO) for 30min at 4°C. All samples were washed and resuspended in 300  $\mu$ L of staining buffer containing 0.1% sodium azide and examined by flow cytometry on a BD LSR II instrument (BD Biosciences, San Jose CA) in the Flow Cytometry Core Facilities of Veterinary Pathobiology or the University of Maryland Department of Microbiology and Immunology. Fifty thousand events were collected, gated for live cells, and analyzed using the FlowJo software (Tree Star Inc., Ashland OR).



### 3. RESULTS

A surface IgL isotype sorting strategy was employed to study the IgH isotypes, V(D)J gene segments, and CDR3 that were found with the IgL  $\kappa$ ,  $\lambda$  and  $\sigma$  isotypes of frog. Although other isotypes are encoded in the IgH locus of *X. laevis* and expressed at low but appreciable levels (24, 25), we focused this study on the IgM, IgX and IgY isotypes dominantly expressed in the spleen and mucosa (26-28 and reviewed in 29).

#### 3.1 IgH/IgL isotype pairing

IgL $\kappa$  and IgL $\sigma$  isotypes enriched at least 12-fold by double-MACS with mouse anti-frog Ig $\kappa$  409B8 and mouse anti-frog Ig $\sigma$  13B2, respectively, against the other IgL isotypes, while Ig $\lambda$  was enriched over 23-fold against Ig $\kappa$ , although only about seven-fold against IgL $\sigma$  isotype by the mouse anti-frog Ig $\lambda$  1E9 mAb (Figure 1A). qPCR of IgH isotypes in these sorted cells showed that IgM dominates in all IgL isotype sorts, but the relative amounts of the IgH isotypes measured did have significant differences. Ig $\kappa$ 's use is skewed to IgY, Ig $\lambda$ 's to IgX, and Ig $\sigma$ 's to IgM (Figure 1B). High  $C_t$  values for IgY of the Ig $\sigma$  sort (all >33) contributed to the large standard error in that IgH/IgL isotype pairing for which we failed to recover a single clone (Figure 1B).

#### 3.2 IgH CDR3 length with different IgL isotypes

In order to examine the V(D)J rearrangements of the IgH isotype that were found in cells sorted by IgL isotype, individual 5' RACE PCR products were cloned and sequenced for each of the nine IgH(M, X, Y)/IgL( $\kappa$ ,  $\lambda$ ,  $\sigma$ ) isotype combinations, with the exception of IgY/IgL $\sigma$  isotype pairing for which no bands were amplified and no clones

were captured (even from “blind” gel excision and cloning from the appropriate migration region of gel lane for the amplicon). A total of 304 cloned IgH amplicons were sequenced, of these 108 had unique sequences in the IgH CDR3 and were assumed to be the product of a unique B lymphocyte clone (Table 1). The amino acid translations of the unique CDR3 clones are displayed in Figure 7, along with the V and J segments used. The assignment of nucleotide origin to germline genomic V, D or J sequences was manually annotated (Figure 8).

Alignment of the CDR3 nucleotide sequences to genomic V(D)J elements allowed discernment of nucleotides not germline encoded (non-template (N) and palindromic (P) nucleotides). Significant differences were not found in the length of CDR3H in different IgH/IgL isotype combinations, although this analysis was limited by the number of clones available from pairings such as IgX and IgY with Ig $\sigma$  (Figure 2A). More or less N and P nucleotides contributing to the CDR3 length also showed no proclivity for particular IgH/IgL isotype pairings (Figure 2B), although the number of retained N and P nucleotide additions after exonuclease activity did correlate with longer CDR3 length (average value  $\bar{x}$ ,  $\pm$  std dev, plots shown in Figure 9). Of the 108 unique clones analyzed, three were not used in CDR3 length analysis due to incomplete V(D)J rearrangement resulting in (D)JC sequences without V segments. Clone 180731 was amplified with an IgX primer but contained an IgY C region sequence and was analyzed as such.

In the entire analysis only one unique CDR3 sequence appeared in two different sorts and was counted in both sets, the IgY clones 020719 from Ig $\kappa$  sort and 060701

from the Ig $\lambda$  sort. This was probably due to the imperfect nature of the sort. Two point mutations in the V gene segment distinguish the clones, presumably from somatic hypermutation as some V's were more heavily mutated away from genomic sequences than others.

### **3.3 *X. laevis* IgH isotype V, D and J use**

We looked for bias in the use of particular IgH V, D or J segments in pairings with particular IgL isotypes. No significant biases were found in the use of D and J elements in cells using particular IgL isotypes (Figure 10). D3, J3, J4 and J6 were not used and D4 only rarely. As mentioned above, some sequences lacked discernable D contributions to CDR3 while others used more than one D. We found no sequences with more than two Ds rearranged.

Although no striking biases were seen with IgHV family use among IgH or IgL isotypes (Figure 3A), an interesting observation was made with IgH V families III and VII, which have considerably longer CDR1 lengths than the other V families of *X. laevis* (Figure 3B) (17). The IgL $\sigma$  isotype sorted cells showed a lower frequency of these two IgH V families (Table 2). Interestingly, the CDR3 lengths of IgHV family III and VII using rearrangements from the Ig $\lambda$  and Ig $\kappa$  sorts is somewhat longer (mean of 9.0 amino acids) than those IgHV family III and IgHV family VII rearrangements from Ig $\sigma$  (mean of 8.7 amino acids).

### 3.4 IgL isotype exclusion

Flow cytometry was performed to more quantitatively determine IgL isotype frequencies suggested by the MACS and RNA recovery (Figure 5 and Table 5). In Figure 5 A-C each IgL isotype was gated (on the top dot plot) then measured for expression of each IgH (bottom three dot plots). Figure 5A is an IgL $\times$ IgH isotype analysis gated on Ig $\kappa$  positive cells and analyzed for percent IgH positive cells. Ig $\kappa$  was 98.3% positive for IgM, .54% positive for IgX, and .71% positive for IgY. Figure 5B is gated on  $\lambda$  positive cells and was 98.6% positive for IgM, 1.55% positive for IgX, and .74% positive for IgY. Figure 5C is gated on Ig $\sigma$  positive cells and was 84.7% positive for IgM, 7.19% positive for IgX, and .57% positive for IgY. In Figure 5 E-G each IgH was gated (top dot plot) then measured for expression of each IgL isotype (bottom three contour maps). This was the reciprocal test of what was done in Figure 5 A-C. Figure 5E is an IgH $\times$ IgL isotype analysis gated on IgM positive cells and analyzed for percent IgL isotype positive cells. IgM was 60.9% positive for Ig $\kappa$ , 23.5% positive for  $\lambda$ , and 1.6% positive for Ig $\sigma$ . Figure 5F is gated on IgX positive cells and was 26.4% positive for Ig $\kappa$ , 34.8% positive for  $\lambda$ , and 32.3% positive for Ig $\sigma$ . Figure 5G gated on IgY positive cells and was 64.3% positive for Ig $\kappa$ , 15.3% positive for  $\lambda$ , and 1.72% positive for Ig $\sigma$ . Figure 5D and 5H are bar graphs of the previously described dot plots and contour maps. Figure 5I is a light scatter gating for lymphocytes, then single cells. Fifty thousand events were collected, gated for live cells, and analyzed as previously described.

Similar relative ratios of Ig $\lambda$ , Ig $\kappa$  and Ig $\sigma$ , respectively, were found as by cell recovery (Table 5). Ig $\sigma$  was expressed much less overall except for IgX. There is a

notable disparity between the lower Ig $\kappa$  expression and higher Ig $\sigma$  expression for IgY. The number of Ig $\kappa$ , Ig $\lambda$ , and Ig $\sigma$  binding cells do not suggest double staining. This allowed us to discount the possibility of cells having more than one IgL isotype expressed. Thus, the spleen B cells of *X. laevis* appear to be isotypically excluded for IgL isotype.

## 4. DISCUSSION

### 4.1 IgL isotype use is far from random in *X. laevis*

Bias in IgH/IgL isotype pairing and differences in CDR lengths show that isotype use is far from random in *X. laevis*. The data in Figure 1B suggest a bias in IgH/IgL isotype pairing in a species with canonical tetrapod class switching and an additional IgL isotype than is found in mammals: a proclivity for IgX/Ig $\lambda$ , IgY/Ig $\kappa$  and Ig $\sigma$  pairing with IgM and IgX but not IgY. A model of this IgH/IgL isotype skewing can be seen in Figure 6. Similar ratios were found using flow cytometry to confirm the IgH/IgL isotype bias (Figure 5). These findings support a previous immunoprecipitation study where Ig $\sigma$  was found to only associate with two of the three IgH isotypes (IgM and IgX), showing a preference for the two T-independent IgH isotypes expressed in the intestines (8). Work in skate showed a large disparity in the ratio of IgL isotype expression based on life stage and location (11). Sharks are biased for Ig $\kappa$  expression (30). If allowed some assumptions (e.g. mRNA coinciding with protein levels), we can interpret these data as reason to expect distinct function in the IgL isotypes of some vertebrates.

Clearly IgL isotype use is not random as described in our qPCR data and flow cytometry and by immunoprecipitation and qPCR and northern blotting in these two previous studies. The next question is where does the preferential binding occur? Our study only examined what happened in the spleen. Is this skewing also present in primary lymphoid tissues, like bone marrow, or did it occur after antigen recognition and class switch recombination (CSR) in secondary lymphoid tissues, like the spleen? We

propose that the bias occurs after antigen exposure and CSR in the secondary lymphoid tissues (Figure 6).

B cell precursors originate in the bone marrow. IgH rearranges first, expressing IgM, then IgL isotypes rearrange. Immature B cells are tested for self-recognition. If self-reactive, it can rearrange V region genes (receptor editing) or die. After antigen exposure in the germinal center, B cells with high affinity surface Ig for the antigen will receive activation signals from antigen on follicular dendritic cells to proliferate and differentiate vs those with low affinity will not receive survival signals and die.

Awkward VH-VL or CH-CL combinations may be caused by steric hindrance and are less likely to occur or survive. Longer CDR1 lengths found in IgHV families III and VII may cause steric hindrance and may explain families being found at a lower frequency with the long CDR2 of Ig $\sigma$  compared to the other IgL isotype sorts. (Table 2 and Figure 3). This steric hindrance is corroborated by threading molecular modeling (Figure 4). The space filling model of VH family III employing IgH from IgL $\sigma$  isotype sort shows crowding of CDR3 IgH by long Ig $\sigma$  CDR2 and VHIII CDR1. As mentioned earlier, the CDR3 lengths of IgHV family III and VII using rearrangements from the Ig $\lambda$  and Ig $\kappa$  sorts is somewhat longer (mean of 9.0 amino acids) than those IgHV family III and IgHV family VII rearrangements from Ig $\sigma$  (mean of 8.7 amino acids), suggesting a further compensation for steric hindrance brought about by the longer IgH CDR1 and IgL CDR2.

Comparing our data on IgH/IgL isotype bias and CDR3 lengths to that of antigen naïve yet mature B cells in the bone marrow could solve the mystery of where (primary

or secondary lymphoid tissue) and when (before or after antigen exposure and CSR) isotype skewing occurs and lead us closer to finding possible functions for IgL isotypes.

#### **4.2 Hints of IgL isotype distinct physiology**

The use of IgH V, D, and J to create diverse combinations of CDR3 is critical to formation of antigen binding sites that protect against countless different pathogens. Post-metamorphosis adult frogs were chosen as more rearrangement diversity (31) and longer CDR3H lengths had been noted in *X. laevis* adults by resolving labeled products on sequencing gels (32). Our sequencing data found CDR3H lengths averaging 10-11 codons similar to previous sequencing gel findings (32). Corresponding CDR3H lengths are found in trout, mice, and human (33, 34). This conservation in size may account for reduced antibody diversity in lower vertebrates. The structure of IgH isotype is similar among vertebrates but the arrangement of the IgH V, D, and J genes differ. Lower vertebrates have a cluster arrangement that does not allow as much combinatorial diversity as the one with multiple repeats of single IgH V, D, and Js (27).

An aside to our central hypothesis is that originally distinct IgL isotypes evolved to pair with products of distinct IgH chain loci in cartilaginous fish. But the IgL isotypes have since (in tetrapods with class switch at a single IgH locus) maintained discrete CDR 1 and 2 lengths to allow at least one isotype to yield a favorable paratope topology when paired with IgH CDR3s of diverse length. The length of CDR3H in *X. laevis* is long for IgH CDR1 and IgL CDR2 in the Ig $\sigma$  sorts but the opposite pattern is seen in the Ig $\kappa$  and Ig $\lambda$  sorts (8, 11). This crowds the CDR3H and is less compatible.



Is it possible that the camelids and sharks that employ some IgH without IgL isotypes (35), or bovidae that use ultralong CDR3 domains (36), are ways of freeing the IgH from the need for IgL isotype fit, and in the process opening up new paratope design space? In this work we have focused on the pairing of the IgL V domain with IgH V, but distinct function could be found in the C domains of IgL isotype as they are in IgH. Alternatively, it has been suggested that steric hindrance could make certain IgL isotype C and IgH isotype C1 domains incompatible (8). The retention of multiple IgL isotypes compounds allelic exclusion with isotype exclusion (5), so there must be advantages that make it worthwhile. In Figure 2, CDR3H lengths were not significantly different amongst IgH/IgL isotype combinations although this analysis was limited by the number of clones available. N and P nucleotides contributing to the CDR3 length also showed no bias in IgH/IgL isotype pairing. Adult *X. laevis*, but not tadpoles, have N and P nucleotides to make CDR3 more diverse (37). There was a correlation between longer CDR3 length and number of retained N and P nucleotide additions after exonuclease activity (Figure 9). No significant bias in the use of D and J segments in IgH of particular IgH isotype and IgL isotype sort were found through sequencing and cloning (Figure 10).

Glycine residues in trout CDRH3 sequences resemble that of *X. laevis* and may contribute to a more flexible conformation in the CDR3 loop allowing greater mobility. This has been hypothesized to help these antibodies bind to a greater variety of antigens (33).

### 4.3 Evolution of IgL isotype physiology

The evolution of Ig isotypes in different classes of vertebrates may be important in the understanding of IgL isotype functions. Jawless fish, do not have immunoglobulins, but instead use variable like receptors for their adaptive immune response (38). IgH, IgM and IgD are found in most jawed vertebrates from cartilaginous fish to mammals. IgY arose in amphibians and later evolved into mammalian IgG and IgE. IgX also emerged in amphibians and is orthologous to the mucosal antibody IgA (2) in reptiles, birds, and mammals. Ig $\lambda$  and Ig $\kappa$  are found in most vertebrates. So far Ig $\sigma$  has only been described from amphibians, teleosts, and cartilaginous fish.  $\sigma$ -cart was discovered in cartilaginous fish, hence the name, but was later found in bony fish as well. Interestingly, there is an overall trend of an increasing number of IgH and decreasing number of IgL isotypes as more recent classes of vertebrates evolved.

Diversity in antigen recognition is crucial for survival and depends upon selection of V genes from IgH and IgL isotypes during B cell development. A decrease in IgL isotype during vertebrate evolution seems counterintuitive. It would appear more logical and advantageous for a greater number of IgL isotypes to be present to give more IgH/IgL combinatorial diversity if that is the role of IgL isotypes. Instead less IgL isotypes are employed for some reason as vertebrates evolved. Perhaps other mechanisms have emerged to compensate for the loss of diversity caused by less IgL isotype V genes to work with?

The platypus is an interesting creature telling of an evolutionary crossroads. Its genome reveals connections to mammals, reptiles, birds, amphibians, and fish (39).

Although the platypus is related to vertebrates, it does not have Ig $\sigma$ . However, highly diverse V Ig $\lambda$  repertoire and CDR lengths may compensate for the lack of IgL isotype diversity in platypus and birds (39).

Other interesting examples of mechanisms that evolved to compensate for the loss of IgL isotype are seen in nurse sharks and camelids. Two very different vertebrate groups have developed antibodies absent of IgL isotype that are highly functional and expressed in equal amount to conventional antibodies with both IgH and IgL isotypes (35). The camel IgH antibody developed from a normal IgH V gene fairly recently whereas the nurse shark Ig is novel and must have been created during an evolutionary event approximately half a billion years ago. Sharks have a multiple cluster Ig VDJ arrangement (VDJ) $n$  compared to other vertebrates that have a translocon organization (VnDnJn). This might give the shark more flexibility to create new Ig loci and thus antibody structures. Camels have adapted to extreme heat and sharks contain a high concentration of urea in their blood that may induce environmental stress contributing to the formation of antibodies absent of IgL isotype (35). It must have been very difficult to create antibodies without IgL isotype (single domain V) since it is has only been described in camelids and sharks so far, but once this mutation appeared, it was seen as highly advantageous because it creates a more diverse projecting single variable domain paratope therefore possibly protecting against more recessed epitopes. Due to the unique conformation of these IgH only antibodies, they are highly effective against certain antigens that antibodies with IgL isotype may not be able to bind to. For example, the IgH only antibodies in camels infected with trypanosomes bind with high affinity to this

parasite (35). Perhaps more species with antibodies absent of IgL isotype will be discovered. Studying the animals that have naturally evolved this unique variation will help us better understand IgL isotype usage and possibly find better treatments for infectious diseases caused by pathogens whose neutralizing epitopes do not bind to conventional antibodies and may have a higher affinity for antibodies without IgL isotype. Hopefully, more variations in IgL isotype use will be found in the future and may help us understand the function of IgL isotypes.

## 5. CONCLUSIONS

We hypothesized that IgL isotypes evolved different functions based on preferences in IgH isotype binding and CDR lengths. Our findings are supportive of this hypothesis. Although more work needs to be done to find possible functions of IgL isotypes, our results for IgH/IgL isotype pairing, IgH CDR3 lengths with different IgL isotypes, *X. laevis* IgH VDJ use, and flow cytometry shed some light on this enigma. For IgH/IgL isotype pairing we found preferential binding between IgX/Ig $\lambda$ , IgY/Ig $\kappa$  and Ig $\sigma$  pairing with IgM and IgX but not IgY. IgH CDR3 length with different IgL isotypes averaged 10-11 codons similar to previous studies (40). We did not find evidence for CDR3H skewing with IgL isotype due to the low number of some clones. N and P nucleotides contributing to the CDR3 length showed no proclivity for particular IgH/IgL isotype pairings, although the number of retained N and P nucleotide additions after exonuclease activity did correlate with longer CDR3 length. *X. laevis* IgH VDJ rearrangements showed no significant bias in use of D and J for cells using particular IgL isotypes. IgHV family use did not show significant bias either, but IgH V families III and VII with longer germline CDR1 lengths than other V families paired with lower frequency to Ig $\sigma$  sorted cells suggestive of steric hindrance causing IgH/IgL isotype pairing bias. Finally, flow cytometry suggested IgL isotype exclusion in spleen B cells of *X. laevis*. These findings will help pave the way for future studies towards discovering functions of IgL isotypes.

The applications of this study will help shed light on the origins and physiological role of mammalian Ig $\lambda$  and Ig $\kappa$  isotypes, their association with IgH, relation to heterodimeric paratopes, and role in IgL isotype associated diseases.

## REFERENCES

1. Zhang YA, et al. IgT, a primitive immunoglobulin class specialized in mucosal immunity. *Nat Immunol.*2010;11:827-835.
2. Mashoof S, et al. Ancient T-independence of mucosal IgX/A: gut microbiota unaffected by larval thymectomy in *Xenopus laevis*. *Mucosal immunology.*2013;6:358-368.
3. Sun Y, Wei Z, Li N, Zhao Y. A comparative overview of immunoglobulin genes and the generation of their diversity in tetrapods. *Dev Comp Immunol.*2013;39:103-109.
4. Edholm ES, Wilson M, Bengten E. Immunoglobulin light (IgL) chains in ectothermic vertebrates. *Dev Comp Immunol.*2011;35:906-915.
5. Nemazee D, Martensson A, Verkoczy L. Haplotype exclusion and receptor editing: irreconcilable differences? *SeminImmunol.*2002;14:191-198.
6. Ota T, Sitnikova T, Nei M. Evolution of vertebrate immunoglobulin variable gene segments. *CurrTopMicrobiolImmunol.*2000;248:221-245.
7. Sverremark E, Rietz C, Fernandez C. Kappa-deficient mice are non-responders to dextran B512: is this unresponsiveness due to specialization of the kappa and lambda Ig repertoires? *IntImmunol.*2000;12:431-438.
8. Hsu E, Lefkovits I, Flajnik M, Du PL. Light chain heterogeneity in the amphibian *Xenopus*. *MolImmunol.*1991;28:985-994.
9. Hadji-Azimi I. Structural studies of the *Xenopus* 19S immunoglobulin and 7S immunoglobulin and two immunoglobulin-like proteins. *Immunology.*1975;28:419-429.
10. Hsu E, Du Pasquier L. Studies on *Xenopus* immunoglobulins using monoclonal antibodies. *MolImmunol.*1984;21:257-270.
11. Miracle AL, et al. Complex expression patterns of lymphocyte-specific genes during the development of cartilaginous fish implicate unique lymphoid tissues in generating an immune repertoire. *IntImmunol.*2001;13:567-580.

12. Criscitiello MF, Flajnik MF. Four primordial immunoglobulin light chain isotypes, including lambda and kappa, identified in the most primitive living jawed vertebrates. *EurJImmunol*.2007;37:2683-2694.
13. Du CC, Mashoof SM, Criscitiello MF. Oral immunization of the African clawed frog (*Xenopus laevis*) upregulates the mucosal immunoglobulin IgX. *Veterinary immunology and immunopathology*.2012;145:493-498.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(-Delta Delta C(T)) Method. *Methods*.2001;25:402-408.
15. Livak KJ, et al. Methods for qPCR gene expression profiling applied to 1440 lymphoblastoid single cells. *Methods*.2013;59:71-79.
16. Rock EP, Sibbald PR, Davis MM, Chien YH. CDR3 length in antigen-specific immune receptors. *J Exp Med*.1994;179:323-328.
17. Haire RN, Amemiya CT, Suzuki D, Litman GW. Eleven distinct VH gene families and additional patterns of sequence variation suggest a high degree of immunoglobulin gene complexity in a lower vertebrate, *Xenopus laevis*. *J Exp Med*.1990;171:1721-1737.
18. Litman GW, et al. Evolutionary development of immunoglobulin gene diversity. *AdvExpMedBiol*.1991;292:11-17.
19. Hsu E, Schwager J, Alt FW. Evolution of immunoglobulin genes: VH families in the amphibian *Xenopus*. *Proc Natl Acad Sci U S A*.1989;86:8010-8014.
20. Biasini M, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. *Nucleic acids research*.2014;42:W252-258.
21. Huston JS, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*. *Proc Natl Acad Sci U S A*.1988;85:5879-5883.
22. Kopp J, Schwede T. The SWISS-MODEL Repository: new features and functionalities. *Nucleic acids research*.2006;34:D315-318.
23. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. *Bioinformatics*.2006;22:195-201.




24. Ohta Y, Flajnik M. IgD, like IgM, is a primordial immunoglobulin class perpetuated in most jawed vertebrates. *Proc Natl Acad Sci USA*.2006;103:10723-10728.
25. Zhao Y, et al. Identification of IgF, a hinge-region-containing Ig class, and IgD in *Xenopus tropicalis*. *Proc Natl Acad Sci USA*.2006;103:12087-12092.
26. Schwager J, Mikoryak CA, Steiner LA. Amino acid sequence of heavy chain from *Xenopus laevis* IgM deduced from cDNA sequence: implications for evolution of immunoglobulin domains. *Proc Natl Acad Sci U S A*.1988;85:2245-2249.
27. Schwager J, Grossberger D, Du Pasquier L. Organization and rearrangement of immunoglobulin M genes in the amphibian *Xenopus*. *EMBO J*.1988;7:2409-2415.
28. Mussmann R, Du PL, Hsu E. Is *Xenopus* IgX an analog of IgA? *Eur J Immunol*.1996;26:2823-2830.
29. Du PL, Schwager J, Flajnik MF. The immune system of *Xenopus*. *Annu Rev Immunol*.1989;7:251-275.
30. Iacoangeli A, et al. Biased Immunoglobulin Light Chain Gene Usage in the Shark. *J Immunol*. 2015 Sep 4. pii: 1501426. [Epub ahead of print]
31. Schwager J, Burckert N, Courtet M, Du Pasquier L. The ontogeny of diversification at the immunoglobulin heavy chain locus in *Xenopus*. *EMBO J*.1991;10:2461-2470.
32. Desravines S, Hsu E. Measuring CDR3 length variability in individuals during ontogeny. *J Immunol Methods*. 1994 Feb 10 ;168(2):219-25.
33. Roman T, De Guerra A, Charlemagne J. Evolution of specific antigen recognition: size reduction and restricted length distribution of the CDRH3 regions in the rainbow trout. *Eur J Immunol*. 1995 Jan;25(1):269-73.
34. Lee A, Desravines S, Hsu E. IgH diversity in an individual with only one million B lymphocytes. *Dev Immunol*. 1993 ;3(3):211-22.
35. Flajnik MF, Deschacht N, Muyltermans S. A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? *PLoS Biol*.2011;9:e1001120.
36. Wang F, et al. Reshaping antibody diversity. *Cell*.2013;153:1379-1393.

37. Schwager J, et al. The ontogeny of diversification at the immunoglobulin heavy chain locus in *Xenopus*. EMBO J. 1991 Sep ;10(9):2461-70.
38. Cannon JP, et al. Variable domains and a VpreB-like molecule are present in a jawless vertebrate. Immunogenetics.2005;56:924-929.
39. Johansson J, et al. High variability in complementarity-determining regions compensates for a low number of V gene families in the lambda light chain locus of the platypus. Eur J Immunol. 2005 Oct ;35(10):3008-19.

APPENDIX A


FIGURES

**Figure 1. IgH isotype message is not equal in cells sorted for IgL isotype.** **A.** Quantification of enrichment of anti-IgL isotype MACS cells by qPCR. Note greater scale of fold enrichment on Ig $\lambda$  sort. **B.** Enrichment-normalized values of IgH isotype message in IgL isotype sorted cells. IgY/ $\sigma$  heterodimers were undetectable by traditional cloning of the sorted cells. Error bars denote standard error of the mean.




**Figure 2. CDR3H lengths not significantly different amongst isotypes. A.** CDR3 length in amino acids between conserved cysteine of YxC motif encoded by the V segment and first conserved glycine of GxG diglycine bulge encoded by the J, measured exclusively, minus four. Data averaged from 104 non-redundant clones in Figure 7, with the standard error of the mean. **B.** Number of N and P nucleotides contributing to the CDR3H, computed in Figure 8 from JGI *X. laevis* genome assembly 7.1.


**A.**



**B.**




**Figure 3. IgH V families III and VII used preferentially with Ig $\kappa$ , not Ig $\sigma$ .** Pie chart shows percentage of clones employing the 11 different IgHV families of *X. laevis* in our clones (n for each isotope heterodimer shown to the bottom right of each chart, in red for biased pairings). **B.** Disparate lengths of CDR1H in VH III and VII versus other families. Conserved cysteine forming intradomain disulfide is highlighted in green of framework (FR) 1 as are conserved WYRQ and glycine of FR2. Shared residues in the long CDR1 of V III and VII are highlighted in yellow (adapted from (17)). IgH families V and XII were not expressed in this sampling.



**Figure 4. SCFV homology modeling supports CDRH1-CDRL2 steric hindrance constraining CDR3H.** **A.** Space filling model of VH family III employing IgH from IgL $\sigma$  sort shows crowding of CDR3 heavy by long Ig $\sigma$  CDR2 and VHIII CDR1. View of antigen binding surface from antigen perspective with coloring as follows: CDR1H red, CDR2H green, CDR3H blue, CDR1L cyan, CDR2L magenta, and CDR3L yellow. **B.** Trace backbone view of same heterodimer modeling with CDRs highlighted the same as in A. perspective from the IgHV side of the molecule rotated slightly towards the CDR2 side of IgL isotype.


**A.**







**B.**







**Figure 5. Flow cytometry.** 5A-C are IgL vs. IgH isotype analysis gated for positive IgL isotype and analyzed for percent IgH isotype positive. 5E-G are the reciprocal analysis of IgL vs. IgH isotype gated for positive IgH isotype and analyzed for percent IgL isotype positive. 5D and H are bar graphs of the scatter plots and contour maps in 5A-C and 5E-F. 5I is a light scatter gating for live lymphocytes.






















**D.**

kappa	IgM	98.3
	IgX	0.54
	IgY	0.71
lambda	IgM	98.6
	IgX	1.55
	IgY	0.74
sigma	IgM	84.7
	IgX	7.19
	IgY	0.57












H. IgM	kappa	60.9
	lambda	23.5
	sigma	1.6
IgX	kappa	26.4
	lambda	34.8
	sigma	32.3
IgY	kappa	64.3
	lambda	15.3
	sigma	1.72





**Figure 6. Model of development of isotype skewing.** This model shows the bias in a IgL isotype for IgH isotypes. Each IgL isotype is given a different color ( $\lambda$  green,  $\kappa$  blue,  $\sigma$  red). Each IgH is represented by a circle. The circles decrease in size to show a decrease in binding preference of the IgL isotype to that IgH.  $\lambda$ ,  $\kappa$ , and  $\sigma$  have the highest affinity for IgM in the primary lymphoid tissue (blue box). In the secondary lymphoid tissue (grey box), after exposure to antigens (labeled Ag), IgL isotypes indicate a bias for the second circle over the third circle. The yellow x is placed over the arrow between IgX and IgY because we failed to recover a single clone for the  $\sigma$  sorted IgY pairing.





**Figure 7. Unique CDR3 amino acid sequences cloned from IgL isotype sorts.** Clone names followed by IgHV family, amino acid sequence with partial aligned V, J and C encoded sequences, followed by the J family at the far right. Conserved cysteine of YxC motif of V and first conserved glycine of the diglycine bulge encoded by the J segment highlighted in grey. Amino acids predicted to be encoded by at least two nucleotides of D segments highlighted magenta for D5, yellow for D1, green for D2, blue for D6, and red for D4. Clones with the same CDR3 as those in alignment are indicated under each set, somatic hypermutations do cause mutations outside of CDR3 in these sequences.

<b>IgM</b>									
<b>IgL κ sort</b>								<IgM C	
510719	III	QSLQGRITVSRDTNKGEVYLKLTGMKPEETAVYYCA	REALWSGV	YYAFDYWGAGTMVTVTSATS	NPPSLF	J5			
520719	VIII	ISESEFKDRVTPSTSGSTAQLRINKLSSSDTATYYCAR	GAYGG	YDFAYWGQGTMTVTVTSATS	NPPSLF	J2			
020729	III	QNLQGRITVSRDTNKGEVYLKLTGMKPEETAVYYC	TAEALAG	PFDYWGQGTMTVTVTSATS	NPPSLF	J7			
040729	I	DSVKGRFTISKDNNNNKLYLQMNNLQTEDTAVYYCAS	DLHWGGS	YAFDYWGAGTMVTVTSATS	NPPSLF	J5			
050729	III	QSLQGRITVSRDTNKGEVYLKLTGMKPEETAVYYC	TGRTLAGS	FDYWGQGTMTVTVTSATS	NPPSLF	J7			
060729	IX	PSYQGRCHISTDNSQGTAFQLNLLKVEDTAMYYCAR	DLGWEG	FAYWGQGTMTVTVTSATS	NPPSLF	J2			
070729	II	ADSLNRVTITKDNGKKQVYLQMTGMEVKDTAMYYCAR	EGN	GDYWGQGTMTVTVTSATS	NPPSLF	J7			
090729	VII	PDLKSRLTLSDRTAKNEAYLEISGMTAGDTAMYYCAK	HGGVTEG	YFEHWGQGTMTVTVTSATS	NPPSLF	J8			
100729	I	DSFKGRFTISRDNNNKLYLQMNNLQTEDTVVYYCAR	DMGSTSG	YWFDYWGQGTMTVTVTSATS	NPPSLF	J7			
110729	IV	SSFQSRVTFTRDTSKNEIYQLQMTSMKSEDSGTYYCA	ISLG	DYAYFDIWIWPGTTVTVTSATS	NPPSLF	J1			
130729	III	QTLQGRITVSRDTNKGEVYLKLTGMKQEETAVYYCA	GAGVA	YFDYWGQGTMTVTVTSATS	NPPSLF	J7			
170729	I	DSVKGRFTISRDNNNKLYLQMNNLQTEDTAVYYCTR	YIPASP	FDYWGQGTMTVTVTSATS	NPPSLF	J7			
180729	II	DSLKNRVTITRDTGKKQVYLQMTGMEVKDTAMYYCARD	LGVGA	FAYWGQGTMTVTVTSATS	NPPSLF	J2			
011202	II	DSLKSRVTITRDTGKKQVYLQMNNGMEVKDTAMYYCAR	EGLEWV	FDYWGQGTMTVTVTSATS	SKPSLF	J7			
021202	II	DSLKNRVTITKDNGKKQVYLQMTGMEVKDTAMYYCAR	VGWGSS	AFDYWGAGTMVTVTSATS	NPPSLF	J5			
031202	III	QSLQGRITVSRDTNKGEVYLKLTGMKPEETAVYYCARE	APASG	YYAFDYWGAGTMVTVTSATS	NPPSLF	J5			

**040729 is the same as:**  
080729                    041202

**090729 is the same as:**  
120729                    160729

**020729 is the same as:**  
190729

**180729 is the same as:**

**IgM**

**IgL λ sort**

020724 IX PSYQGRCHISTDNSQSTAFQLNLLKVEDTAMYYCAR  
031113 VIII ISESEFKERVTPSTSGSTAQLRISKLSSSDTATYYCAT  
041113 IV PSFQSRITLTRDTSKNEISLQMTSMKSADSGTYYCAR  
071113 X KSVEGRLVITRNNAEQVTFMELKNLVYQDTAVYYCTR  
091113 IV PSFQSRVTLTRDTSKNEISLQMTSMKSADSGTYYCTR  
111113 IX PSYQGRCHISTDNSQSTGFLQLNLLKVEDTAMYYCARS  
141113 VI PAFQNRVTLTRDTAKNEIYLAVSSMRSEDSGTYYCA  
131121 I DSVKGRFTISRDNNNNNLYLQMNLLQTEDTAVYYCARD  
191121 II DSLKNRVTITKDNGKKQVYLMQMGMEVKDTAMYYCARE  
241121 III TTVQGRLTLSDTNKGEVYFKLTEAKTEESATYYCAR  
011125 II DSLKSRVTITRDTGKKQVYLMQMGMEVKDTAMYYCAR  
021125 II DSLKNRVTITKDNGKKQVYLMQMGMEVKDTAMYYCARD  
061125 II DSLKNRVTITKDNGKKQVYLMQMGMEVKDTAMYYCARD  
121125 II DSLKNRVTITKDNGKKQVYLMQMGMEVKDTAMYYCARD  
131125 I DSVKGRFTISRDNNNNNLYLQMNLLQTEDTAVYYCARD  
181125 I DSVKGRFTISRDNNNNNLYLQMNLLQTEDTAVYYC  
031126 II DSLKNRVTITKDNGKKQVYLMQMGMEVKDTAMYYC  
061126 III QSLQGRITVSRDTNKGEVYFKLTGMKQEETAVYYCA  
121126 III TTVQGRLTLSDTNKGEVYFKLTEAKTEESATYYCARQ

VRGP  
YRGVA  
RI  
YRGVA  
SGV GAY  
ALAGGP  
RGGG  
IGGVTA  
LAHWGG  
YRGT  
TEVQ  
ASGY  
PLAGT  
KGN  
KWSGSG  
VRGSRYSS  
SCRYG  
RLAGTAG

<IgM C

/GDYWGQGTMTVTSATSNNPSSLF J7  
YFAYWGQGTMTVTSATSKSPSLF J2  
HFDYWGQGTMTVTSATSKSPSLF J7  
NAFDYWGAGTMVTVTSATSKSPSLF J5  
HFDYWGQGTMTVTSATSKSPSLF J7  
FEHWGQGTMTVTSATSKSPSLF J8  
FAYWGQGTMTVTSATSNNPSSLF J2  
GYFEHWGQGTMTVTSATSNNPSSLF J8  
FDYWGQGTMTVTSATSNNPSSLF J7  
NWFYWGQGTMTVTSATSKSPSLF J7  
SFAYWGQGTMTVTSATSKSPSLF J2  
LDYWGQGTMTVTSATSKSPSLF J7  
RYFEHWGQGTMTVTSATSKSPSLF J8  
AWFDYWGQGTMTVTSATSNNPSSLF J7  
HFDYWGQGTMTVTSATSKSPSLF J7  
YFDYWGQGTMTVTSATSNNPSSLF J7  
DFAYWGQGTMTVTSATSNNPSSLF J2  
NWFYWGQGTMTVTSATSKSPSLF J7  
FAYWGQGTMTVTSATSKSPSLF J2

**020724 is the same as:**

030724	040724	060724	080724	090724	100724
110724	120724	130724	140724	150724	160724
170724	180724	190724	200724	230724	270724
280724	290724	300724			

**041113 is the same as:**

101113	081121	141121	171121	201121	211121
141125	161125	211125	221125	161126	201126

**071113 is the same as:**

051121	151121	041125	191126
--------	--------	--------	--------

**091113 is the same as:**

161121	221121	031125	071125	081125
--------	--------	--------	--------	--------

021125 is the same as:  
091125 151125

011125 is the same as:  
111125

131125 is the same as:  
231125

241121 is the same as:  
181126 241126

121125 is the same as:  
221126

**IgM**

IgL  $\sigma$  sort

						<IgM C
021009	II	DSQSRVTITRDTGKKQVYLQMTGMEVKDTAMYYCA	EAYGGGRG	NWFDYWGQGMVTVTSATSNPPLF	J7	
031009	b	PSYQGRCHISTDNSQSTAFQLNLLKVEDTAMYYCAR		/GDYWGQGMVTVTSATSNPPLF	J7	
071009	IX	PSYQGRCHISTDNSQSTGFLQLNLLKVEDTAMYYCAR	A	SHFDYWGQGMVTVT*ATSNPPSLF	J7	
081009	II	DSLKNRVTITKDNGEKQVYLQMTGMEVKDTAMYYCAR	YAGGT	NAFDYWGAGTMVTVTSATSKSPSLF	J5	
111009	II	DSLKNRVTITKDNGKKQVYLQMTGMEVKDTAMYYCA	KYGG	YNGFDYWGAGTMVTVTSATSNPPLF	J5	
151009	III	QSLKGRITVSRDTNKGEVYLKLTGMKPEETAVYYCA	RGLTGVG	LAYWGQGMVTVTSATSNPPLF	J2	
191009	II	DSLKNRVTITKDNGKKQVYLQMTGMEVKDTAMYYCARE	GGSF	AFDYWGAGTMVTVTSATSNPPLF	J5	
241009	I	DSVKGRFTISRDNNNKLYLQMNLLQTEDTAVYYCAR	PTSGYP	FAYWGQGMVTVTSATSNPPLF	J2	
011001	I	DSVKGRFTISKDNNNKLYLQMNLLQTEDTAVYYCTRE	GGGS	WFDYWGQGMVTVTSATSNPPLF	J7	
011014			LFLSVWGT	GAFDYWGAGTMVTVTSATSNPPLF	J5	
041014	II	DSLKNRVTITRDTGKKQVYLQMTGMEVKDTAMYYCAR	PYASG	YYAFDYWGAGTMVTVTSATSNPPLF	J5	
111014	I	DSVKGRFTISRDNNNKLYLQMNLLQTEDTAVYYCAR	SPGV	YYAFDYWGAGTMVTVTSATSNPPLF	J5	
121014	I	DSVKGRFTISRDNNNKLYLQMNLLQTEDTAVYYCAT	ED	IYYAYFDIWGP GTT VTVTSATSNPPLF	J1	
131014	I	DSVKGRFTISRDNNNKLYLQMNLLQTEDTAVYYCAT	GWGSNS	YFEYWGQGMVTVTSATSNPPLF	J8	
161014	IX	PSYQGRCHISTDNSQSTGFLQLNLLKVEDTAMYYCAR	GGI	YAFDYWGAGTMVTVTSATSNPPLF	J5	
191014	I	DSVKGRFTISRDNNNKLYLQMNLLQTEDTAVYYCARD	GAWSK	DYFDYWGQGMVTVTSATSNPPLF	J7	
201014	IX	PSYQGRCHISTDNSQSTAFQLNLLKVEDTAMYYCAR		/YWGQGMVTVTSATSNPPLF	J7	
221014	I	DSVKGRFTISRDNNNKLYLQMNLLQSED TAVYYCTR	GGVASGYA	YAYFDIWGP GTT VTVTSATSNPPLF	J1	
011016	II	DSLKNRVTITRDTGKKQVYVQMTGMEVKDTAMYYCA	TGVGG	AYFDIWGP GTT VTVTSATSNPPLF	J1	

021016	III	TTVEERLTLSRDPNKGEVYFKLTEARTEESATYYCARH	ARGWQ	NFDYWGQGTMTVTTSATS	NPPSLF	J7	
081016	II	DSLKNRVTITKDNGKKQVYLQMTGMEVKDTAMYYCARD	EERGGSA	YWGQGTMTVTTSATS	NPPSLF	J2	
091016	I	DSVKGRFTISRDNNNKLYLQMNQLQTEDTAVYYCAR	WAGVG	DAYFDIWGP GTT	VTVTSATS	NPPSLF J1	
101016	III	TTVEERLTLSRDPNKGEVYFKLTEARTEESATYYCARH	ARGWQ	DFDYWGQGTMT	TATSATS	NPPSLF J7	
201016	I	DSVKGRFTISKDNNNKLYLQMNQLQTEDTAVYYCAS	DLHWGGS	YAFDYWGAGTM	VTVTSATS	NPPSLF J5	
241016	IV	SSFQSRVTFTTRDTSKNEIYLQMTSMKSEDSGTYYCAR	YASGY	RRAF	FDYWGAGTM	VTVTSATS	NPPSLF J5
121009			GERG	AFDYWGAGTM	VTVTSATS	NPPSLF J5	

**031009 is same as:**

041009	051009	061009	091009	101009	131009
141009	171009	181009	201009	211009	231009
031014	051014	141014	211014	241014	021014
111016	121016	151016	181016	211016	

**241009 is same as:**

011002	031001	051001
--------	--------	--------

**081009 is same as:**

010924	020924	030924	040924	050924	060924
070924	080924	090924	100924	110924	120924
130924	140924	150924	160924	170924	180924
190924	200924	210924	220924	230924	240924

**011014 is the same as:**

061014	071014	091014	101014	151014	171014
181014	231014	031016	041016	071016	141016
171016	221016	161009	221009	011009	

**221014 is the same as:**

051016

**191014 is the same as:**

061016

**161014 is the same as:**

131016	231016
--------	--------

091016 is the same as:  
161016

221014 is the same as:  
191016

**IgX**

**IgL κ sort**

150729	III	QSLKGRITVSRDTNKGEVYLKLTGMKPDETAVYYCA	RAE	LDYWGGQGMVTVTSVTASAPSVF	J7
011205	I	DSVKGRFTITRDNNNNKLYLQMNNLQTEDTAVYYCAR	SSGV	NWYFEHWGGQGMVTVTSVTASAPSVF	J8
021205	I	DSVKGRFTISRDNNNKLYLQMNNLQTEDTAVYYCTRD	SGG	FDYWGGQGMVTVTSVTASAPSVF	J7
031205	II	DSLKNRVTITRD TGKKQVY LQMNGIEVKDTAMYYCAR	GLRGV	FDYWGGQGMVTVTSVTASAPSVF	J7
061205	VII	PDLKSRLTL SRDTVKNEAYLEISGMTAGDTAMYYCAK	HGLLEWDYA	FDYWGAGTMVTVTSVTASAPSVF	J7
091205	I	DSVKGRFTISRDNNNKLYLQMNNLQTEDTAVYYCATE	MGG	FAYWGGQGMVTVTSVTASAPSVF	J2
101205	VII	PGLKSRLTL SRDTAKNEDYLEISGMTAGDTAMYYCAKQ	FTGL	GSYFDYWGGQGMVTVTSVTASAPSVF	J7

150729 is the same as:  
160729                      170729                      180729

011205 is the same as:  
041205                      111205

021205 is the same as:  
071205

061205 is the same as:  
081205

101205 is the same as:  
111205

**IgX**

**IgL λ sort**

010701	II	DLMKNRVKITKDNGKKEVYLQMTGMEVKDTAMYYCTR	TRTLTYTGK	WFDYWGGQGMVTVTSVTASAPSVF	J7
020701	IV	PSFQSRVTL SRDTSKNEISLQMTSMKSEDSGTYYCAR		HDFAYWGGQGMVTVTSVTASAPSVF	J2
040701	II	DTLKNRVTITRD TGKEQVY LQMNGMEVKDTAMYYCAR	YMFWSGTNV	FDYWGAGTMVTVTSVTASAPSVF	J5
030727	X	KSVEGRLVITRNNAEQVTFMELKNLVYQDTAVYYCTR	DSGVGV	FDYWGGQGMVTVTSVTASAPSVF	J7

040727	II	DSLKNRVTITKDTGKKQVY LQM NEM EVKDTAMYYCARD	RLGEV	TEAFDYWGAGTMVTVTSVTASAPSVF	J5
280727	III	QSLKGRITLSRDTNKGEVYLKLTGMKPEETAVYYCAR	DTVGP	AFDYWGAGTMVTVTSVTASAPSVF	J5
050727	III	TTVQGRLTLSRDTNKGEVYFKLTEAKTEESATYYCAR	YYVSGYK	YAYFDIWGPGTTVTVTSVTASAPSVF	J1
080727	I	DSVKGRLTISRDNNNNKLYLQMNNLQTEDTAVYYCTR	SGVGP	YFDYWGQGTMTVTVTSVTASAPSVF	J7
090727	III	QSLQGRITVSRDTNKGEVYLKLTGMKREETALYYCTNY	RGGGTS	DYFDYWGQGTMTVTVTSVTASAPSVF	J7
140727	IX	PSYQGRCHISTDNSQSTGFLQLNNLKVEDTAMYYCAR	KERVQP	FAYWGQGTMTVTVTSVTASAPSVF	J2
190727	I	DSVKGRFTISRDNNNNKLYLQMNNLQTEDTAVHYC	AFFCSGSSG	TFDYWGAGTMVTVTSVTASAPSVF	J5
260727	III	YAMQGRLTLSRDTNKGEVYFKLTETKTEESATYYCARQ	TGVA	NYFDYWGQGTMTVTVTSVTASAPSVF	J7
300727	II	DSLKNRVTITKDTGKKQVY LQM NEM EVKDTAMYYCAS	TGVG	DFAYWGQGTMTVTVTSVTASAPSVF	J2
300731	II	DSLKNRVTITKDNQKKQVY LQM TGM EVKDTAMYYCARD	YAGGT	NAFDYWGAGTMVTVTSATSKSPSLF	J5
070731	II	DSLKNRVTITKDNQKKQVY LQM TGM EVKDTAMYYCARD	TEVQ	LDYWGQGTMTVTVTSATSKSPSLF	J7
100731	III	TAVQGRLTLSRDTNKGEVYFKLTEAKTEESATYYCAR	SLTGVA	HFAYWGQGTMTVTVTSATSKSPSLF	J2
130721	II	DSLKSRVTITRNTGKKQVY LQM NGM EVKDTAMYYCAR	EPYGGY	NAFDYWGAGTMVTVTSATSKSPSLF	J5
140731	II	DTLKNRVTITRNTGKKQVY LQM NGM EVKDTAMYYCAR	YDWVGA	YFEHWGQGTMTVTVTSATSKSPSLF	J8
190731	III	QNLQGRITVSRDTNKGEVYLKLTGMKPEETAVYYC	VGG	FDYWGQGTMTVTVTSATSNPPSLF	J7
230731	IV	PSFQSRITLTRDTSKNEISLQMTSMKSADSGTYYCAR	YRGVA	HFDYWGQGTMTVTVTSATSKSPSLF	J7

**020701 is the same as:**

030701                    070727

**030727 is the same as:**

020727                    100727

**040727 is the same as:**

160727

**050727 is the same as:**

200727

**140727 is the same as:**

210727                    220727

**080727 is the same as:**

270727

**190727 is the same as:**

010727

**IgX**

**IgL α sort**

180919	IV	PSFQSRVTLSRDTSKNEISLQMTSMKSEDSGTY	CARH
091024	IV	PSFQSRVTLSRDTSKNEISLQMTSMKSEDSGTY	CASH

			<IgX C
DFAY	WGQ	TMVTVTSVTASAPSVF	J2
DFAY	WGQ	TMVTVTSVTASAPSVF	J2

**180919 is same as:**

130919	140919	150919	160919	170919	010919
030919	060919	050919	070919	080919	021022
031022	011024	021024	031024	041024	051024
061024	071024	081024	101024	111024	121024
131024	141024	151024	161024		

**IgY**

**IgL κ sort**

010719	IX	SSYQGRCHISTDNSQSTAFQLNNLKVEDTAMYY	CA	TEAF	GVGP
020719	I	DSLKGRFIIISRDNNKNNLYLQMNNVQTEDTAVYY	CTRE	VRL	GV
060719	I	DSLKNRVTITRDTGKKQVYLQMTGMEVKDTAIYY	C	AKTE	WDA
100719	I	DLIKGRFTISRDNNNNKLYLQMNNIQTEDTAVYY	CARD		GD
160719	II	DYLKNRVTITKDNVKKQVYVQMTGMEVKDTAMYY	CAR	L	GDWG
290719	I	DSVKGRFTISRDNNNNKLYLQMNNLQTEDTAVYY	CTR		CGEG

			<IgY C
WYFEH	WGQ	TMVTVTSATLHAPSVF	J8
FDY	WGAG	TMVTVTSATLHAPSVF	J7
FDY	WGAG	TMVTVTSATLHAPSVF	J7
HAYFDI	WGP	TTVTVTSATLHAPSVF	J1
DFGY	WGQ	TMATVTSATLHAPSVF	J2
AYFDI	WGP	TTVTVTSATLHAPSVF	J1

**020719 is the same as:**

030719	040719	050719	070719	080719	110719
120719	170719	190719	200719	210719	250719
280719	300719				

**100719 is the same as:**

180719	240719
--------	--------

**010719 is the same as:**

260719
--------

**IgY**

**IgL λ sort**

050701	II	DYLKNRVTITKDNQKQVYVQMTGMEVKDTAMYYCSR	LGDWG	DFAYWGQGMVTVTSATLHAPSVF	J2
060701	I	DSLKGRFIIIRDNNKNNLYLQMNNVQTEDTAVYYCTRE	VRIGVT	FDYWGAGTMVTVTSATLHAPSVF	J7
070701	I	DSLKGRFTISRDNNNKLYLQMNNLQTEDTAGYYCAR	HVGTLAGP	NWFDYWGQGMVTVTSATLHAPSVF	J7
010709	I	DSVKGRFTISRDNNNKLYLQMNNLQTEDTAVYYCTRD	SGGSPYYA	FDYWGAGTMVTVTSATLHAPSVF	J7
030709	I	DSVKGRFTISRDNNNKLYLEMNNLQTEDTAVYYCAS	QHRYGAPPAS	YDFAYWGQGMVTVTSATLHAPSVF	J2
040709	II	DYLKNRVTITKDNVKKQVYVQMTGLEVKDTAMYYCAR	LGDWG	DFGYWGQGMVTVTSATLHAPSVF	J2
050709	I	DSLKGRFTISRDNNNKLYLQMNNLQTEDTAVYYCAR	HVGTLAGP	NWFDYWGQGMVTVTSATLHAPSVF	J7
070709	I	DSLKGRFTISRDNNNKLYLQMNNLQTEDTAVYYCTR		GWFDYWGQGMVTVTSATLHAPSVF	J7
080709	II	DYLKNRVTITKDTGKKQVYVQMTGMEVKDTAMYYCTR	VS	YGNWFDYWGQGMVTVTSATLHAPSVF	J7
110709	I	DSVKGRFTISRDNNNKLYLQMNNLQTEDTAVYYCAR	LGLNA	FDYWGAGTMVTVTSATLHAPSVF	J7
120709			VGG	GQGMVTVTSATLHAPSVF	J7
180731*	II	DSLKNRVTITKDNQKQVYVQMTGMEVKDTAMYYCAS	TLAVTALPA	FDYWGQGMVTVTSATLHAPSVF	J7

<IgY C

\*cloned with IgX primer

**070701 is the same as:**

080701                    020709

**060701 is the same as:**

060709                    090709

**040709 is the same as:**

100709

**IgY**

**IgL σ sort**

none cloned




Figure 8. Nucleotide alignments of IgH isotype clone CDR3s.


Clone	V	V	×	N/P	× D5 >N/P×	D1 >>N/P×	D2 >N/P×	D6 >N/P×	D4 >	N/P	×	J	> J	N/P total	CDR3H
					TGGGGTGG	ACGCTAGCGGGTACA	TACGGGGGC	GGGAGTGGG	GGCTACG						
IgH/Igκ	Y	Y	C									W	G	×	G
510719	III	TATFACTGTGC		TAGAGAGCCCTCTGGAG	TGGG		CT	TACGGGG		TA		TACTATGCTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	20	12
520719	VIII	TATATTGTGC AAG		A	GGG					TT		ATGACTTTGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	5	9
020729	III	TATFACTGT		ACTGCTGAGGCC	TGGGGTGG	CTAGCGGG				CCC		CTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	15	8
040729	I	TATFACTGTGCTAG		TGACTTTCAC	TGGGGTGG					GAG		CTATGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	13	11
050729	III	TATFACTGT		ACTGGCCGT	TGGGGTGG	ACGCTAGCGGGTACA				G		CTTTGACTACTGGGGACAMGGAACTATGGTCACTGTACACATCA	J7	10	8
060729	IX	TATFACTGTGCTAGA		GACT	TGGGGTGG					GAGGG		CTTTGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	9	8
070729	II	TATFACTGTGC AAGAGA		AGGGA								GACTACTGGGGACAMGGAACTATGGTCACTGTACACATCA	J7	5	5
090729	VII	TATFACTGTGC AAGACA		T						ACGG		GGTATTTCGAGCACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J8	12	10
100729	I	TATFACTGTGCTAGAGA		CA	TGGGGT	CTAGCGGGT					AGTAAACAGAGG	ACTGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J7b	5	11
110729	IV	TACTACTGTGCAA		TCTCAT						GGGG		ACTATGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J1	7	12
130729	III	TATFACTGTGC		T						GGAG		ACTACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	13	8
170729	I	TATFACTGTACTAGA		TACATTTC		CGCTAGC				CC		CTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	10	8
180729	II	TATFACTGTGC AAGAGA		TC	TGGG	AGT				CC		TTTGGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	7	8
011202	II	TATFACTGTGC AAGAGA			GGGT	CT				T		CTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	3	8
021202	II	TATFACTGTGC AAGAG			TGGGGTGG	GGT				CTC		TGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	6	10
031202	III	TATFACTGTGCTAGAGA		AGCCCC		CGCTAGCGGG						TACTATGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	6	11
IgH/Igκ	Y	Y	C									W	G	×	G
020724	IX	TATFACTGTGCTAG		G								TGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	1	2
031113	VIII	TATATTGTGC AAGC		G						CCT		ACTTTGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	4	7
041113	IV	TATFACTGTGC AAGA		TATA						CAC		ACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	7	8
071113	X	TATFACTGTAC AAGA		AGGATCA						GTGG		ATGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	7	6
091113	IV	TATFACTGTAC AAGA		TATAGG	TGGGGTGG					CAC		ACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	9	8
111113	IX	TATFACTGTGCTAGAG		TTCTGGGA	GTGG					GAGC		GTATTTCGAGCACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J8	11	9
141113	VI	TATATTGTGCA		G		CGCTAGCGGGT				GGCC		CTTTGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	6	7
131121	I	TATFACTGTGCTAGAGA		CA	TGGGGTGG	G	AGCG					GGTATTTCGAGCACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J8	3	9
191121	II	TATFACTGTGC AAGAGAGA		TT						AACAGC		CTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	8	9
241121	III	TATATTGTGC AAG				GTAGC	TCAC			TGGG		AACTGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J7b	8	10
011125	II	TATFACTGTGC AAGA		TACC						ACGT		CTTTGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	8	7
021125	II	TATFACTGTGC AAGA		CACGGGA		GGTACA				GC		TTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	8	7
061125	II	TATFACTGTGC AAGAGA				CGCTAGCGGGTACA						GGTATTTCGAGCACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J8	0	9
121125	II	TATFACTGTGC AAGAGA		CC		CGCTAGCGGGTACA				GC		CTGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J7b	4	10
131125	I	TATFACTGTGCTAGAGA		TAAA						ACC		ACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	7	7
181125	I	TATFACTGT		AAATGGA	GTGG	AGCGGG				GGGA		TACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	8	7
031126	II	TATFACTGTG		TAA	TGGGGT	TCGA	GGTACA			GCTC		TGACTTTCGATTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	11	9
061126	III	TATFACTGTGC		TAGTTCGA								AACTGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J7b	10	8
121126	III	TATATTGTGC AAGACA		ARG		GCTAGCGGGTACA	G			GGGG		TTTGGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	4	10
IgH/Igκ	Y	Y	C									W	G	×	G
021009	II	TATFACTGTGCA		GAAGCT						TGGCAGAGGG		AACTGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J7b	16	11
031009	IX	TATFACTGTGCTAG		G								TGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	1	2
071009	IX	TATFACTGTGCTAGA		TC								ACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	2	5
081009	II	TATFACTGTGC AAG		GTAC		GCGGGT				GGCAC	AGC	ATGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	10	10
111009	II	TATFACTGTGCAA		AG		GGGT				G		TACAAGTGGTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	3	9
151009	III	TATFACTGTGC		TAGAGTCTCAC	TGGGGTGG					GAC		TTGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	15	8
191009	II	TATFACTGTGC AAGAGAG			TGGGGTGG	AGCGGGTAC				CAGCTT		TGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	6	8
241009	I	TATFACTGTGCTAGA		CCCACC						CCT		TTTGGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	5	8
011014	I	TATFACTGTACTAGAGA		GG	TGGGGTGG					GAG		CTGGTTCGATTACTGGGGACAMGGAACTATGGTCACTGTACACATCA	J7b	9	8
011014	II	TATFACTGTGC AAGA		CCGT		ACGCTAGCGGG						GCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	4	10
111014	I	TATFACTGTGCTAGA		TCCCCTG	TGGGGTGG							TACTATGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	6	9
121014	I	TATFACTGTGCTAGAG		GACAT								CTACTATGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J1	5	9
131014	I	TATFACTGTGCTACAG		GC						ABCAGT		TATTTGAGTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J8	8	9
161014	IX	TATFACTGTGCTAGA		GG						T		CTATGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	3	7
191014	I	TATFACTGTGCTAGAGA		T						TTG		ACTACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	10	15
201014	IX	TATFACTGTGCTAG		G								TGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	1	0
221014	I	TATFACTGTAC AAGAG		GG		CGCTAGCGGGTAC				GC		CTATGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J1	4	13
011016	II	TATFACTGTGCAA		C	TGGGGTGG					GGG		TGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J1	5	8
021016	III	TATATTGTGC AAGACA		TGCTCG	TGGGGTGG					CAGA		ACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	10	9
081016	II	TATFACTGTGC AAGAGA		TAGAGA						GGCTCTGG		TACTATGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J2	15	8
091016	I	TATFACTGTGCTAGA		TGGC	TGGGGTGG					GAG		ATGCTTACTTTCGACTCTGGGGACAMGGAACTATGGTCACTGTACACATCA	J1	8	10
101016	III	TATATTGTGC AAGACA		TGCTCG	TGGGGTGG					CAGG		ACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	10	9
201016	I	TATFACTGTGCTAG		TGACTTTCAC	TGGGGTGG					GAG		CTATGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	13	11
241016	IV	TACTACTGTGC AAG		GT		ACGCTAGCGGGTACA				GGCG		TGCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5	6	10
121009					TGGGGTGG	A						GCTTTCGATTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J5		
Igκ/Igκ	Y	Y	C									W	G	×	G
150729	III	TATFACTGTGC		TAGAGCTGAAC								TTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	11	4
011205	I	TATFACTGTGCTAGA		TCCTCT						GGAGTGG		AACTGGTATTTCGAGCACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J8	6	9
021205	I	TATFACTGTACTAGAGA		CTC						GGGGG		CTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	3	6
031205	II	TATFACTGTGC AAGAG		GCT		TACGGGG				GT		CTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	5	7
061205	VII	TATFACTGTGCAA		ACA	TGGG	CTTCT				ACTATGCT		TTGACTACTGGGGCGCTGGAAACAAATGGTCACTGTACACATCA	J7b	16	11
091205	I	TATFACTGTGCTACAGA		AAT						G		CTTTGCTTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J2	4	6
101205	VII	TATFACTGTGC AAGACA		GTTCACTGGGT	TGGGGTGG					C		CTACTTTGACTACTGGGGACAMGGAACTATGGTCAACGCTCACTCA	J7	12	10

Clone	V	V	N/P	D5	D1	D2	D6	D4	N/P	J	J	N/P total	CDR3H
<u>Igλ/Igλ</u>	Y	Y	C							W G x G			
010701	II	TATTACTGTACAAAG	ACGAGGACGTTAARATA	TGGGGTGG	ACCGTAGCGGGTACA	TACGGGGGC	GGGGAGTGGGG	GGCTACG	CAAG	TGGTTCGATTACTGGGGCAAGGTACCATGGTCACTGTACATCA	J7b	21	12
020701	IV	TATTACTGTGCAAGACA				TACATGTC	TGGAGT	GGGA	CCAATGT	TGACTTTGCTTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	0	4
040701	II	TATTACTGTGCAAGA							GT	TTTCGATTACTGGGGCGTGGAAACATGGTCACTGTACATCA	J5	17	11
030727	X	TATTACTGTCAAGA	GATTCT					GGAGTGGGG	AG	CTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J7	8	8
040727	II	TATTACTGTGCAAGAGA	TAGACCT	GGTG	AAGTA	ACGG			C	GCCTTCGATTACTGGGGCGTGGAAACATGGTCACTGTACATCA	J5	14	11
280727	III	TATTACTGTGCTAGA	GATACCGT						AAA	TGCTTCGATTACTGGGGCGTGGAAACATGGTCACTGTACATCA	J5	9	8
050727	III	TATTACTGTCAAGA	TACTACGT		TAGCG				AAA	TATGCTTACTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J1	11	12
080727	I	TATTACTGTACTAGA	TC						GACC	CTACTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J7	6	8
090727	III	TATTACTGT	ACTAATAT	GGGGGTGG			G	GTGGG	ACCTCGG	ACTACTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J7	17	11
140727	IX	TATTACTGTGCTAGAA	AGG		AGCGGGTACA				GCC	CTTTGCTTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	6	8
190727	I	CATTACTGT	GCTTTTTCTGCA	GTGG	GAGTT				A	CTTTGATTACTGGGGCGTGGAAACATGGTCACTGTACATCA	J5	19	10
260727	III	TATTACTGTGCAAGACA	GA					GTGG	CAA	ACTACTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J7	5	9
300727	II	TATTACTGTGCAAG	TAC	GGGGGTGG					GC	GACTTTGCTTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	5	7
030731	II	TATTACTGTGCAAG	GTAC		GGCGGT	GGCAC			A	ATGCTTTCGATTACTGGGGCGTGGAAACATGGTCACTGTACATCA	J5	10	10
070731	II	TATTACTGTGCAAGAGA	CACGGG		GGTACA				GC	TTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J7	8	7
100731	III	TATTACTGTGCAAGA	TCCT					GTGG	CTC	ACTTTGCTTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	8	9
130731	II	TATTACTGTGCAAG	GGAGCC						A	ATGCTTTCGATTACTGGGGCGTGGAAACATGGTCACTGTACATCA	J5	8	10
140731	II	TATTACTGTGCAAGA	TACGAC	GGGG				GGGG	AGC	GTATTTGAGCACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J8	9	9
190731	III	TATTACTG	C						GAGG	CTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J7	5	3
230731	IV	TATTACTGTGCAAGA	TATAGGG	GGGTGG					CAC	ACTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J7	10	8
<u>Igλ/Igκ</u>	Y	Y	C							W G x G			
180919	IV	TATTACTGTGCAAGACA								TGACTTTGCTTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	0	4
091024	IV	TATTACTGTGCAAGTCA								TGACTTTGCTTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	0	4
<u>Igλ/Igκ</u>	Y	Y	C							W G x G			
010719	IX	TATTACTGTGCTA	CTGAAGCATT					GGAGTGGG	ACC	CTGGTATTTGAGCACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J8	14	11
020719	I	TATTACTGTACTAGAGA	AGTTCGGT					GGGAGT	TACT	TTGATTATGGGGCGTGGAAACATGGTCACTGTACATCA	J7b	13	9
060719	I	TATTACTGT	GC AAAA AACTGA	GTGG					GATGCT	TTTCGATTACTGGGGCGTGGAAACATGGTCACTGTACATCA	J7b	17	7
100719	I	TATTACTGTGCTAGAGA	T					GGGA	TC	ATGCTTACTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J1	3	8
160719	II	TATTACTGTGCAAG	GT				AC	TGGGG		TGACTTTGGTATGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	5	8
290719	I	TATTACTGTACTAGA	TGT					GGGAG	GGG	GCTTACTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J1	6	8
<u>Igλ/Igλ</u>	Y	Y	C							W G x G			
050701	II	TATTACTGTTCAAG	GT					GGGG	AC	TGACTTTGCTTATGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	5	8
060701	I	TATTACTGTACTAGAGA	AGTTCGGT					TGGG	AGTTACT	TTGATTATGGGGCGTGGAAACATGGTCACTGTACATCA	J7b	15	9
070701	I	TATTACTGTGCTAGA	CATGTCGGT		ACCGTAGCGGGT				CC	CACCTGGTTCGATTACTGGGGCAAGGAACTATGGTCACTGTACATCA	J7b	11	12
010709	I	TATTACTGTACTAGAGA			TAGCGG			TGGG	AGCCCTTACTAGTCT	TTTCGATTACTGGGGCGTGGAAACATGGTCACTGTACATCA	J7b	14	11
030709	I	TATTACTGTGCTAG	CCAACRCGA			TACGGG			CCCTCCGGCTCAT	ATGACTTTGCTTATGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	25	14
040709	II	TATTACTGTCAAG	GT					GGGG	AC	TGACTTTGGTATGGGGCAAGGAACTATGGTCAACGTCACATCA	J2	5	8
050709	I	TATTACTGTGCTAGA	CATGTCGGTACGCC		AGCGGGT			TGGG	CC	CACCTGGTTCGATTACTGGGGCAAGGAACTATGGTCACTGTACATCA	J7b	16	12
070709	I	TATTACTGTACTAGAG	G							CTGGTTCGATTACTGGGGCAAGGAACTATGGTCACTGTACATCA	J7b	1	4
080709	II	TATTACTGTCAAGAG	TCTCA			TACGG			CC	CACCTGGTTCGATTACTGGGGCAAGGAACTATGGTCACTGTACATCA	J7b	5	8
110709	I	TATTACTGTGCTAGA	CT		CGGG				CTCAATGCT	TTTCGATTACTGGGGCGTGGAAACATGGTCACTGTACATCA	J7b	11	7
120709								GTGGG	AGGT	GGCAAGGTACCATGGTCACTGTACATCA	J7		
180731	II	TATTACTGTGCAAG	TACGT		TAGCGG	T	TACGG	CC	TACCTGG	CTTTGACTACTGGGGCAAGGAACTATGGTCAACGTCACATCA	J7	15	12


**Figure 9. Correlation of N/P nucleotide additions with CDR3 length.**




Adj  $R^2 = 0.0090958$   
Intercept = 1.9514 Slope = 0.38616




Adj  $R^2 = 0.69761$   
Intercept = -16.123 Slope = 2.0225




Adj  $R^2 = 0.56338$   
Intercept = -12.678 Slope = 1.7662



Adj  $R^2 = 0.034894$   
Intercept = -2.3476 Slope = 0.86585





Adj  $R^2 = -0.18475$   
Intercept = -2.1754 Slope = 0.94737



Adj  $R^2 = 0.14625$   
Intercept = -3.9545 Slope = 1.0455

**Figure 10. Use of D and J segments in IgH isotype of particular IgH and IgL isotype sort.** **A.** Use of the six germline D segments. Several use two different D's serially in the same CDR3, some use none (or they were exonucleated away). **B.** Use of nine germline J segments (scaled to 100% as each sequence has one J). No IgY/Ig $\sigma$  sequences were cloned.



APPENDIX B

TABLES

**Table 1. IgH clones sequenced by IgL isotype sort.**

IgH	IgL	Total	Unique	Duplicate CDR3	no V	FS
M	κ	22	16	6	-	-
M	λ	68	19	49	-	1
M	σ	99	26	73	2	2
X	κ	15	7	8	-	-
X	λ	30	20	10	-	-
X	σ	30	2	28	-	-
Y	κ	23	6	17	-	-
Y	λ	17	12	5	1	-
Y	σ	-	-	-	-	-

**Table 2. Use of long CDR1 VH families III and VII by IgL isotype.**

	Ratio	%
IgLκ	9/29	31.0%
IgLλ	9/49	18.4%
IgLσ	3/26	11.5%

**Table 3. Primers used.**

Code	Name	5'-3' Sequence	T <sub>m</sub> C°
<b>MFC 158</b>	XIB2MF1	AAC ATT AGT CCC CCG GTG G	60.0
<b>MFC 159</b>	XIB2MR1	GGG AGA CCA CAC ATT CCA CT	60.0
<b>MFC 201</b>	IgMC3-F	AAC ACA CAG AGC TGG CTT CA	58.4
<b>MFC 202</b>	IgMC4-R	AGC ATG TCA AGG TGG CAG TT	58.4
<b>MFC 203</b>	IgXC3-F	GTG TTT GTG CTG AGG ACT GG	60.5
<b>MFC 204</b>	IgXC4-R	TAG TTC TTG AGC GGA TGG TG	58.4
<b>MFC 230</b>	IgYC3-F2	CCT GAT CTT CCA TCA CCA	53.8
<b>MFC 231</b>	IgYC4-R4	CCC TCT TCT TCT TCT TCC	53.8
<b>MFC 435</b>	IgLambdaC-F1	T ACA GGT GAC GTG AAA GCC C	60.0
<b>MFC 437</b>	IgLambdaC-R1	AGC GAT GGG TTG TTG GAG AG	60.0
<b>MFC 234</b>	IgKappaC-F1	AGT TCC TCC GAC GTT AAG AC	58.4
<b>MFC 235</b>	IgKappaC-R1	CTC TGT GTC AGT TGT GCT GT	58.4
<b>MFC 236</b>	IgSigmaC-F1	CAG TAA GCC TGG TCA ATG TG	58.4
<b>MFC 237</b>	IgSigmaC-R1	GAA GCC AGG GTC AAG TAA C	57.5

**Table 4. Limits of IgH genomic V and J sequences.**

V or J segment	Orientation	Last base	Scaffold
VH I	S	839144	29869
VH II	AS	7017527	13576
VH III	AS	6937997	13576
VH IV	AS	6902258	13576
VH VI	AS	6896015	13576
VH VII	AS	6969838	13576
VH VIII	S	1043406	29869
VH IX	S	59820	272406
VH X	S	1297421	29869
J1	AS	6822054	13576
J2	AS	6821835	13576
J5	AS	6820764	13576
J7	AS	6821611	13576
J7b	AS	6820149	13576
J8	AS	6821325	13576

**Table 5. Cells and RNA recovered after IgL isotype sorts.**

	Starting Cell Number	Final Cell Number	ratio	RNA(ug)
IgL $\kappa$	$6.1 \times 10^7$	$5.07 \times 10^6$	.083	.536
IgL $\lambda$	$3.84 \times 10^7$	$3.57 \times 10^6$	.092	.110
IgL $\sigma$	$6.1 \times 10^7$	$1.15 \times 10^6$	.018	.226